FDA
-
-
-
-
-
-
-
Cara Therapeutics (CARA) Prioritizes Late-Stage Notalgia Paresthetica Program, Extends Cash Runway into 2026
-
-
-
-
-
-
-
Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
-
-
-
-
-
-
-
Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
-
-
-
-
-
-
-
Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
-
-
-
-
-
-
-
Cara Therapeutics (CARA) Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in NEJM
-
-
-
-
-
-
-
KemPharm (KMPH) Announces Appointment of Christopher Posner as New Independent Director
-
-
-
-
-
-
-
Cara Therapeutics to Present at Upcoming Investor Conferences
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

